TP53 and cancer: Therefore, several strategies have been proposed to restore P53 function and, among the compounds developed for the reactivation of mutated P53 [10], PRIMA-1MET (2-(hydroxymethyl)-2-(methoxymethyl)quinuclidin-3-one or APR-246) has been shown to boost antitumor activity in several cancer cells [11,12,13,14].